Brain Metastatic Lung Cancer Patients: A Multitarget Therapeutic-Supportive Strategy with Anti-STAT3 Silibinin

Area of Science:

• Oncology
• Neurology
• Pharmacology

Background:

• Lung cancer patients with brain metastases require management to maintain quality of life (QoL).
• New therapies crossing the blood-brain barrier are crucial for treating brain metastases.
• Novel molecules are being developed as adjuvant treatments for cancer patients with brain metastases.

Purpose of the Study:

• To evaluate the safety and efficacy of silibinin as an adjuvant therapy for lung cancer patients with brain metastases.
• To assess the impact of silibinin on the quality of life (QoL) in this patient population.

Main Methods:

• A descriptive, observational, retrospective study was conducted.
• Data from 86 lung cancer patients with brain metastases treated with silibinin and standard therapy were collected.
• Safety profile and QoL benefits of silibinin were the primary endpoints.

Main Results:

• Silibinin demonstrated a favorable safety profile, with only one mild adverse event reported.
• Patients receiving silibinin maintained good quality of life over time.
• Improvements in neurological symptoms and overall patient well-being were observed in some cases.

Conclusions:

• This study represents the first large collection of lung cancer patients with brain metastases treated with silibinin.
• Silibinin is well-tolerated and supports good quality of life in patients.
• Silibinin shows potential as an effective adjuvant therapy for managing brain metastases in lung cancer.